Welcome to our dedicated page for Corvus Pharmaceu SEC filings (Ticker: CRVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) SEC filings page on Stock Titan provides access to the company’s public reports as filed with the U.S. Securities and Exchange Commission. Corvus is a Delaware-incorporated, clinical-stage biopharmaceutical company whose common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Global Market. Its filings give structured detail on operations, risk factors, capital structure and governance as it advances immunotherapy programs for cancer and immune diseases.
Through this page, you can review current and periodic reports such as Forms 8-K, which Corvus uses to announce material events including financial results, business updates and board of director changes. For example, recent 8-K filings have furnished press releases on quarterly financial results and described the appointment of a new director to the Board and its committees.
Investors researching CRVS can also use this section to locate annual reports (Form 10-K) and quarterly reports (Form 10-Q), where available, which typically discuss the company’s clinical-stage pipeline, including the ITK inhibitor soquelitinib, the adenosine A2a receptor inhibitor ciforadenant and the anti-CD73 antibody mupadolimab. These filings often outline key clinical programs such as the registration Phase 3 trial in relapsed/refractory peripheral T cell lymphoma and trials in atopic dermatitis and Autoimmune Lymphoproliferative Syndrome.
Stock Titan enhances these documents with AI-powered summaries that highlight important sections, helping readers quickly identify information on clinical development, collaborations, equity structure and risk disclosures without reading every page. Real-time updates from EDGAR mean new CRVS filings, including any future Forms 4 related to insider transactions or proxy statements on executive and director compensation, can be reviewed promptly from a single, organized interface.
Corvus Pharmaceuticals director Andrew C. Chan received a grant of stock options for 30,000 shares of common stock. The options have an exercise price of $16.02 per share and expire on April 23, 2036. All 30,000 options were reported as directly owned following the grant.
The footnote explains that these options vest in three equal annual installments. One-third of the shares subject to the option will vest on each annual anniversary starting April 23, 2026, as long as Chan continues his service relationship with Corvus on each vesting date.
Corvus Pharmaceuticals, Inc. director Andrew C. Chan filed a Form 3, which is an initial statement of beneficial ownership for insiders. The filing lists him as a director and shows no reportable insider transactions, purchases, or sales at this time.
BlackRock, Inc. amends a Schedule 13G to report ownership of 5,387,818 shares of Corvus Pharmaceuticals common stock, representing 6.4% of the class. The filing shows sole voting power for 5,320,965 shares and sole dispositive power for 5,387,818 shares as reported on 04/27/2026.
The amendment cites aggregated holdings across BlackRock reporting business units and notes various clients/beneficiaries may have rights to dividends or proceeds. Exhibit references include a Power of Attorney and an Item 7 exhibit identifying relevant subsidiaries.
Corvus Pharmaceuticals, Inc. is holding a fully virtual annual meeting of stockholders on June 11, 2026 at 1:00 p.m. Pacific Time. Holders of 84,090,424 common shares as of April 16, 2026 can vote online, by phone or by mail on three main proposals.
Stockholders will vote on electing two Class I directors (Richard A. Miller and Linda S. Grais), ratifying PricewaterhouseCoopers LLP as independent auditor for 2026, and approving on a non-binding advisory basis the compensation of named executive officers. The board recommends votes in favor of all three proposals.
Corvus Pharmaceuticals appointed Andrew C. Chan, M.D., Ph.D. to its Board of Directors, effective April 23, 2026. He will serve as a Class II director with a term expiring at the 2027 annual stockholder meeting and will also join the Nominating and Corporate Governance Committee.
Under the company’s non-employee director compensation program, Dr. Chan will receive a $35,000 annual cash retainer for Board service and an initial stock option for 30,000 shares of common stock under the 2016 Equity Incentive Award Plan, plus $4,000 annually for Nominating Committee service. On the same date, longtime director Scott Morrison notified the company of his resignation from the Board, effective April 23, 2026.
The Vanguard Group filed Amendment No. 1 to a Schedule 13G for Corvus Pharmaceuticals Inc, reporting 0 shares beneficially owned of Common Stock and 0% ownership as stated in the amendment dated 03/13/2026. The filing states Vanguard reorganized internally on January 12, 2026, and certain subsidiaries now report ownership separately in reliance on SEC Release No. 34-39538.
The signature block shows the filing was signed by Ashley Grim, Head of Global Fund Administration, on 03/26/2026.
Corvus Pharmaceuticals, Inc. established an amended at-the-market equity program to sell up to $200,000,000 of common stock through Jefferies LLC as sales agent under a newly filed automatic shelf registration on Form S-3.
The new Amended and Restated Open Market Sale Agreement replaces a prior $100,000,000 arrangement under which no shares had been sold as of March 13, 2026. Jefferies will use commercially reasonable efforts to place shares by various permitted methods and may earn a commission of up to 3.0% of the gross sales price per share.
Registers up to $200,000,000 of common stock for sale in an amended at-the-market program. Corvus Pharmaceuticals amended its open market sales agreement with Jefferies to increase the maximum aggregate offering price from $100,000,000 to $200,000,000, with Jefferies serving as sales agent. The company has not sold shares under the prior agreement and suspended the prior program effective January 20, 2026. Sales, if any, will be made from time to time on the Nasdaq Global Market under an at the market plan; Jefferies may receive up to 3.0% of gross proceeds as compensation. The prospectus cites a March 11, 2026 last reported sale price of $16.90 and states shares outstanding of 74,696,629 as of December 31, 2025.
Corvus Pharmaceuticals, Inc. has filed a Form S-3 shelf registration to allow the company to offer from time to time common stock, preferred stock, debt securities, warrants and units under a single shelf prospectus. The shelf permits multiple offerings after the registration statement is effective.
The prospectus notes the company’s common stock trades on Nasdaq under the symbol CRVS and cites a March 11, 2026 last reported sale price of $16.90 per share. The prospectus also discloses capital structure details (authorized common and preferred shares) and that, as of December 31, 2025, Pre-Funded Warrants to purchase up to 8,275,913 shares were outstanding.
Corvus Pharmaceuticals files its Annual Report describing a late-stage immunology and oncology pipeline built around T‑cell modulation. The lead drug, soquelitinib, is in a registrational Phase 3 trial for relapsed peripheral T‑cell lymphoma and a Phase 2 trial for moderate‑to‑severe atopic dermatitis.
Earlier Phase 1 work in atopic dermatitis showed meaningful EASI score reductions versus placebo and favorable safety. Corvus is also advancing ciforadenant in kidney cancer and mupadolimab for future oncology and infectious disease uses, supported by a broad global patent estate.
As of June 30, 2025, non‑affiliate common stock market value was about $251.9 million, and as of March 12, 2026, 83,992,407 common shares were outstanding.